Identifying biomarkers for cancers linked to BRCA1 mutations
Official title: Biomarkers For BRCA1-Deficient Cancers
Funded at University of Texas Hlth Science Center · NIH-11094694 · Data updated 2026-11-12
This study is looking at how changes in the BRCA1 gene affect breast and ovarian cancer cells and how this might help us create new treatments that specifically target those cancer cells, which could be especially helpful for patients with BRCA1 mutations.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | June 1, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $436,807 |
| NIH project number | 5R01CA279971-02 |
| Project ID | NIH-11094694 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with breast or ovarian cancer who have BRCA1 mutations.
✕Less likely to help
Patients without BRCA1 mutations or those with other types of breast or ovarian cancer may not benefit from this research.
What this research studies
This research investigates the role of BRCA1 mutations in breast and ovarian cancers, focusing on how these mutations affect the Unfolded Protein Response (UPR) in cancer cells. By understanding the relationship between BRCA1 and UPR stress sensors, the study aims to develop new treatment strategies that specifically target BRCA1-deficient cancer cells. Patients with these mutations may benefit from therapies designed to exploit the vulnerabilities created by their cancer's unique biology. The research employs both in vitro and in vivo methodologies to explore these connections and potential treatment avenues.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with BRCA1-deficient cancers.
How similar studies have gone: Previous research has shown promising results in targeting UPR pathways in cancer, indicating potential for success in this novel approach.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Kong, Kimi Y — University of Texas Hlth Science Center
- Study coordinator: Kong, Kimi Y
Related research
Other NIH-funded projects on the same topics.
-
LRP1 controls NSC movement and stroke recovery
This NIH grant studies how a brain receptor called LRP1 helps neural stem cells move to stroke injuries and support recovery in adults.
-
Rural microvascular factors driving brain aging and dementia
This project will study how blood vessel problems in rural communities contribute to brain aging and dementia, using mobile clinics to reach people who live far from major medical centers.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Gene editing therapies to prevent epileptic seizures
A new gene-editing approach aims to reduce seizures in people with epilepsy by directly modifying a brain gene tied to the condition.
-
Blocking the IL-4/13 pathway in allergic asthma and rhinoconjunctivitis to understand why treatments work differently
A high-quality clinical trial will test a targeted therapy in people with allergic asthma and allergic rhinitis to understand why symptoms and responses vary.
-
Hormonal Influences on Inflammation in Endometriosis
A study in adult women with endometriosis looks at how hormones and immune pathways interact to influence inflammation and symptoms.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.